Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT07238608
Recruiting Observational

Impact of UFPs and MNPs on Fetal Health

NCT07238608 · tracked via the Priya Life Science Spain tracker
Sponsor
Instituto de Investigacion Sanitaria La Fe
Phase
Observational
Started
2026-01-01
Last updated
2025-11-20

Condition(s) studied

Pregnant Women

Study summary

This project aims at unravelling mechanisms by which exposure to air pollution (in particular Ultrafine Particulate (UFP, PM0.1), and micro nano plastic's) interferes with the normal foetus development, with a short-term causal effect in higher likeliness of preterm delivery which, in consequence, precondition a higher likeliness to suffer non-communicable diseases (NCD) later in the life.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Agreement to sign the informed consent; * Non-smoking mothers and no exposure to environmental (second-hand) smoke (smoking influences UFP measurements); * ≥18 years old (mothers have to place sensors, mothers with childhood pregnancies may live at their parental home); * Not expecting to terminate the pregnancy (no measurements of the child); * Having resided in the geographical area of research for a minimum period of 1 year (to be eligible for modeling exposures). Exclusion Criteria: * First visit after 11 weeks of gestation (to ensure 2-week monitoring in the first trimester); * Pregnancy complications that limit exposure measurements in urine (because it may cause polyuria, for example, gestational diabetes); * Known kidney disease (might influence exposure measurements in urine); * Multiple pregnancy (twin or more pregnancies may have a higher risk for complications or preterm birth, no measurements in the last trimester).

Primary outcome measure(s)

  • PreTerm Birth — at the moment of birth
  • Small for Gestational Age — at the moment of birth
  • Low Birth Weigth — at the moment of birth

Trial sites (1)

FacilityCityRegionStatus
Instituto de Investigación Sanitaria La Fe Valencia Valencia Recruiting

More Instituto de Investigacion Sanitaria La Fe trials in Spain

Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II) Recruiting
Compative Study of PE in Thrombosed AVF After Balloon Thrombectomy Vs. Thromboaspiration. Recruiting
Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA) Active, not recruiting
Exercise to Fight Obesity Recruiting
Perceptions of Key Domains of Home-Based Palliative Care Among Healthcare Professionals (MULTIPAL) Enrolling by invitation

Other trials for the same condition

Oral Health Education for Pregnant Women Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07238608 on ClinicalTrials.gov ↗ ← All trials in Spain